

Supplementary Table 1. Patient demographics before match

	Overall N = 44,501	Non-FCD N = 41,732 (93.8)	FCD N = 2,769 (6.2)	<i>P</i>
Age, mean (SD)	45.6 (15.5)	45.6 (15.4)	46.9 (16.6)	< .001
Female sex	23,884 (53.7)	22,468 (53.9)	1,398 (50.5%)	.001
Malnutrition	510 (1.2)	371 (0.9)	139 (5.0)	< .001
Payer type				
Commercial	40,368 (90.7)	37,941 (90.9)	2,427 (87.7)	
Medicare	4,133 (9.3)	3,791 (9.1)	342 (12.4)	< .001
Anti-TNF therapy*	11,581 (26.0)	10,571 (25.3)	1,010 (36.5)	< .001
CCI				
0	24,710 (55.5)	23,313 (55.9)	1,397 (50.5)	
1	9,419 (21.2)	8,858 (21.2)	561 (20.3)	
2+	10,372 (23.3)	9,561 (22.9)	811 (29.3)	< .001

All data are n (%) unless otherwise stated.

*Anti-TNF therapy included adalimumab, certolizumab pegol, ustekinumab, vedolizumab, and infliximab

CCI, Charlson Comorbidity Index; CD, Crohn's disease; FCD, fibrostenotic Crohn's disease; SD, standard deviation; TNF, tumor necrosis factor.